Answers are grounded in this paper and cite their sources.
Tyrosine kinase inhibitors, antibody drug conjugate in monotherapy and combinations are emerging strategies in many HER2-positive cancers; HER2 therapies are now part of standard of care of HER2-amplified gastric or gastroesophageal junction cancer. Data are pending on several unmet medical needs.
No takes yet. Share an insight, caveat, or question.
Gaye et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: